ClariTrial — AI Clinical Trial Intelligence

Precision Medicine ApproachHormones and Medications tailored to lab tests, combined with devices that support stress management and brain exercisesStandard-of-Care+1 more

Alzheimer's Prevention and Reversal Project, Inc.73 participants6 sites · United StatesCompletes Oct 2025

CT.gov Full analysis →

NCT01466088

Completed

Efficacy, Safety, & Tolerability of AZD3480 Patients With Mild to Moderate Dementia of the Alzheimer's Type (AD)

Phase 2Alzheimer's Disease

DonepezilAZD3480

Targacept Inc.386 participants33 sites · United States, Czechia, RomaniaCompletes May 2014

CT.gov Full analysis →

NCT07392723

Recruiting

ALA-enriched Nutrition for Prevention of Cognitive Decline in APOE4 Older Adults

Phase 2Cognitive DysfunctionAlzheimer DiseaseBlood-Brain Barrier

Alpha-Linolenic Acid (2.6 g/day)Placebo Control Group

Michal Schnaider Beeri, Ph.D.20 participants1 site · United StatesCompletes Apr 2027

CT.gov Full analysis →

NCT07234695

Recruiting

LEvetiracetam to Prevent Seizures in Symptomatic Alzheimer's Disease in Adults With Down Syndrome

Phase 3Down SyndromeDown Syndrome (DS)Down Syndrome (Trisomy 21)

Levetiracetam 500mgPlacebo

Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau120 participants5 sites · SpainCompletes Dec 2027

CT.gov Full analysis →

NCT00486044

Completed

Results posted

Evaluating Simvastatin's Potential Role in Therapy

Phase 2Alzheimer Disease

SimvastatinPlacebo

University of Wisconsin, Madison103 participants1 site · United StatesCompletes Jun 2009

CT.gov Full analysis →

NCT06748625

Active

Efficacy of a Multidomain Intervention on Lifestyle Risk Factors for Dementia Prevention

Phase 3Risk BehaviorCognitive Decline

Luci Coach-Assisted Intervention

LuciLab370 participants1 site · CanadaCompletes Mar 2026

CT.gov Full analysis →

NCT02707458

Completed

Dosage and Efficacy of Probucol-induced apoE to Negate Cognitive Deterioration

Phase 1Phase 2Dementia of the Alzheimer TypeAge-related Cognitive DeclineMild Cognitive Impairment Due to Alzheimer Disease

Probucol

Douglas Mental Health University Institute23 participants1 site · CanadaCompletes Mar 2017

CT.gov Full analysis →

NCT04840992

Completed

Phase I/II Clinical Trial of Recombinant Novel Coronavirus (COVID-19) Vaccine (Adenovirus Type 5 Vector) for Inhalation

Phase 1Phase 2COVID-19

Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) for InhalationRecombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)Placebo for Inhalation+1 more

CanSino Biologics Inc.840 participants1 site · ChinaCompletes Jul 2022

CT.gov Full analysis →

1–15 of 76

Explore/Alzheimer's disease prevention trials Phase 2 Phase 3

Status

Phase

76 results for “Alzheimer's disease prevention trials Phase 2 Phase 3”

Page 1 of 6

NCT05109169

Recruiting

METformin and FINGER Intervention to Prevent Cognitive Impairment and Disability in Older Adults at Risk for Dementia

Phase 2Cognitive DeclineCognitive ImpairmentDementia

FINGER 2.0 multidomain lifestyle-based interventionSelf-guided multidomain lifestyle intervention

Imperial College London600 participants3 sites · Finland, Sweden, United KingdomCompletes Feb 2027

CT.gov Full analysis →

NCT06563895

Recruiting

Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant

Phase 3AmyloidosisAmyloid CardiomyopathyTransthyretin Amyloidosis

AcoramidisPlacebo oral tablet

Eidos Therapeutics, a BridgeBio company582 participants94 sites · United States, Argentina, AustraliaCompletes Oct 2031

CT.gov Full analysis →

NCT03417986

Completed

Phase 2Alzheimer Disease

TEP

Immungenetics AG20 participants2 sites · GermanyCompletes Jul 2021

CT.gov Full analysis →

NCT06797817

Not Yet Recruiting

Tributyrin Treatment in Mild Alzheimer Disease: Assessment of Butyrate Effects Via the Gut-Brain

Phase 3Alzheimer Disease (AD)

tributyrinPlacebo

Universidad de Almeria156 participants1 site · SpainCompletes Sep 2026

CT.gov Full analysis →

NCT00000176

Completed

Alzheimer's Disease Prevention Trial

Phase 3Alzheimer DiseaseMemory Disorders

EstrogenEstrogen and Progesterone

National Institute on Aging (NIA)22 sites · United StatesCompletes Sep 2007

CT.gov Full analysis →

NCT02191267

Completed

Results posted

Tau Imaging of Chronic Traumatic Encephalopathy

Phase 2Chronic Traumatic Encephalopathy

[F18]-T807[F18]-FlorbetapirMRI/MRS+1 more

Brigham and Women's Hospital30 participants2 sites · United StatesCompletes Sep 2016

CT.gov Full analysis →

NCT06384573

Active

DIAN-TU Amyloid Removal Trial (ART) in Dominantly Inherited Alzheimer's Disease

Phase 3Alzheimer's DiseaseDementiaAlzheimer's Disease, Familial

lecanemab

Washington University School of Medicine40 participants6 sites · United States, Australia, United KingdomCompletes Jun 2030

CT.gov Full analysis →

NCT05894954

Completed

Precision Medicine Approach for Early Dementia & Mild Cognitive Impairment

Phase 3Mild Cognitive ImpairmentDementia, Mild

Precision Medicine ApproachHormones and Medications tailored to lab tests, combined with devices that support stress management and brain exercisesStandard-of-Care+1 more

Alzheimer's Prevention and Reversal Project, Inc.73 participants6 sites · United StatesCompletes Oct 2025

CT.gov Full analysis →

NCT01466088

Completed

Efficacy, Safety, & Tolerability of AZD3480 Patients With Mild to Moderate Dementia of the Alzheimer's Type (AD)

Phase 2Alzheimer's Disease

DonepezilAZD3480

Targacept Inc.386 participants33 sites · United States, Czechia, RomaniaCompletes May 2014

CT.gov Full analysis →

NCT07392723

Recruiting

ALA-enriched Nutrition for Prevention of Cognitive Decline in APOE4 Older Adults

Phase 2Cognitive DysfunctionAlzheimer DiseaseBlood-Brain Barrier

Alpha-Linolenic Acid (2.6 g/day)Placebo Control Group

Michal Schnaider Beeri, Ph.D.20 participants1 site · United StatesCompletes Apr 2027

CT.gov Full analysis →

NCT07234695

Recruiting

LEvetiracetam to Prevent Seizures in Symptomatic Alzheimer's Disease in Adults With Down Syndrome

Phase 3Down SyndromeDown Syndrome (DS)Down Syndrome (Trisomy 21)

Levetiracetam 500mgPlacebo

Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau120 participants5 sites · SpainCompletes Dec 2027

CT.gov Full analysis →

NCT00486044

Completed

Results posted

Evaluating Simvastatin's Potential Role in Therapy

Phase 2Alzheimer Disease

SimvastatinPlacebo

University of Wisconsin, Madison103 participants1 site · United StatesCompletes Jun 2009

CT.gov Full analysis →

NCT06748625

Active

Efficacy of a Multidomain Intervention on Lifestyle Risk Factors for Dementia Prevention

Phase 3Risk BehaviorCognitive Decline

Luci Coach-Assisted Intervention

LuciLab370 participants1 site · CanadaCompletes Mar 2026

CT.gov Full analysis →

NCT02707458

Completed

Dosage and Efficacy of Probucol-induced apoE to Negate Cognitive Deterioration

Phase 1Phase 2Dementia of the Alzheimer TypeAge-related Cognitive DeclineMild Cognitive Impairment Due to Alzheimer Disease

Probucol

Douglas Mental Health University Institute23 participants1 site · CanadaCompletes Mar 2017

CT.gov Full analysis →

NCT04840992

Completed

Phase I/II Clinical Trial of Recombinant Novel Coronavirus (COVID-19) Vaccine (Adenovirus Type 5 Vector) for Inhalation

Phase 1Phase 2COVID-19

Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) for InhalationRecombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)Placebo for Inhalation+1 more

CanSino Biologics Inc.840 participants1 site · ChinaCompletes Jul 2022

CT.gov Full analysis →

1–15 of 76